Albireo Pharma (ALBO) Reports Q3 Loss of $1.17, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Albireo Pharma (ALBO) Reports Q3 Loss of $1.17, Revenues Miss

Albireo Reports Third Quarter 2018 Financial Results

November 13, 2018 7:00 AM EST

Odevixibat selected as International Nonproprietary Name (INN) for A4250

A4250 granted Fast Track and additional Orphan Drug designations

A4250 Phase 3 trial progressing as planned, new natural history data presented at AASLD

Management to host conference call and webcast today at 8:30 a.m. EST

BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the third quarter ended September... More